Bristol-Myers Squibb's patent infringement suit against Merck over a new cancer treatment can move forward, a Delaware federal judge has ruled.
March 21, 2016 at 12:35 AM
1 minute read
The original version of this story was published on Delaware Business Court Insider
Bristol-Myers Squibb’s patent infringement suit against Merck over a new cancer treatment can move forward, a Delaware federal judge has ruled.
In Bristol-Myers Squibb v. Merck & Co., U.S. District Judge Gregory M. Sleet of the District of Delaware denied Merck’s motion to dismiss Bristol-Myers’ complaint. Merck argued that Bristol-Myers’ patent for the cancer treatment was not valid.
Presented by BigVoodoo
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
